apatinib has been researched along with Liver-Diseases* in 2 studies
2 other study(ies) available for apatinib and Liver-Diseases
| Article | Year |
|---|---|
[Clinical analysis of liver dysfunction induced by SHR-1210 alone or combined with apatinib and chemotherapy in patients with advanced esophageal squamous cell carcinoma].
Topics: Antineoplastic Combined Chemotherapy Protocols; Esophageal Neoplasms; Esophageal Squamous Cell Carcinoma; Humans; Liver Diseases; Programmed Cell Death 1 Receptor; Prospective Studies | 2023 |
Low-dose apatinib in subjects with renal impairment: A pharmacokinetics study.
In patients with renal impairment, we studied apatinib and its major metabolites (M1-1, M1-2, M1-6, and M9-2) for pharmacokinetics.. Subjects with different renal functions were given a single oral dose of apatinib mesylate tablets of 250 mg. Pharmacokinetic samples were collected at 1 hour before dosing,0.25, 0.5, 1, 2, 3, 4, 6, 8, 24, 48, 72, and 96 h after dosing. The pharmacokinetic parameters of apatinib and its major metabolites were calculated by noncompartmental analysis.. Comparing PK parameters of the mild or moderate renal impairment group with the healthy group: the geometric mean ratios of maximum observed drug concentration (C. Patients with mild and moderate renal impairment do not need to adjust the dose of apatinib when using low dose (250 mg) apatinib. Topics: Area Under Curve; Humans; Kidney; Liver Diseases; Pyridines | 2023 |